Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register
| Autor: | Emma C. Tallantyre, Ruth Dobson, Tim Friede, Martin Duddy, Richard Nicholas, Alasdair Coles, Rachael Hunter, David V. Ford, Linda A Middleton, Owen R Pearson, Roshan dasNair, Stella Hughes, Rodden M. Middleton, Katherine A Tuite-Dalton, David Rog, Nikos Evangelou, W. J. Rodgers, Afagh Garjani, Elaine M Craig |
|---|---|
| Přispěvatelé: | Garjani, Afagh [0000-0001-9271-346X], Dobson, Ruth [0000-0002-2993-585X], Tallantyre, Emma Clare [0000-0002-3760-6634], Nicholas, Richard [0000-0003-0414-1225], Apollo - University of Cambridge Repository |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Ethnic group Clinical Neurology Disease multiple sclerosis 03 medical and health sciences 0302 clinical medicine Epidemiology medicine Sibling 10. No inequality Expanded Disability Status Scale business.industry Multiple sclerosis PostScript medicine.disease 3. Good health Psychiatry and Mental health Family medicine Cohort epidemiology Observational study Surgery Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Neurology, Neurosurgery & Psychiatry Journal of Neurology, Neurosurgery, and Psychiatry |
| ISSN: | 1468-330X 0022-3050 |
| DOI: | 10.1136/jnnp-2020-324449 |
| Popis: | In the early phases of the UK COVID-19 outbreak, in the absence of clear evidence about the risks for people with multiple sclerosis (pwMS) and those taking immunomodulatory disease-modifying therapies (DMT), we launched a community-based study as part of the UK MS Register (UKMSR). We intended to capture the picture of COVID-19 among pwMS and their risk of contracting the disease. Here, we report our findings from 17 March to 24 April 2020. The COVID-19 study (clinicaltrials.gov:NCT04354519) is a prospective observational cohort launched on 17 March 2020 as part of the UKMSR (Ethics:16/SW/0194). PwMS completed a specific COVID-19 related survey which was combined with data held from before the pandemic where available. The primary outcome of the study is participant-reported self-diagnosis of COVID-19. Participants were asked if their diagnosis was confirmed by testing—the available test in the UK was reverse transcriptase-PCR. Participants reported if their sibling without MS, closest in age who was not living with them, had self-diagnosed COVID-19. The likelihood of having COVID-19 was assessed using multivariable regression analysis with the variables: age, gender, ethnicity, MS duration and type, self-isolation and DMTs. DMTs were considered after stratifying based on moderate-efficacy versus high-efficacy therapies (table 1). Disability was assessed using the last recorded web-based Expanded Disability Status Scale (webEDSS) or MS Impact Scale v2 (MSIS-29v2). View this table: Table 1 Distribution of individual disease-modifying therapies (DMTs) among participants of the COVID-19 study As of 24 April, out of 3910 participants, 237 (6.1% (95% CI 5.3% to 6.8%)) reported self-diagnosed COVID-19 among whom 54 (22.8% (17.5% to 28.2%)) also had a diagnosis by a healthcare professional based on symptoms and 37 (15.6% (11.2% to 20.6%)) a confirmed diagnosis by testing. Three participants reported hospitalisation due to COVID-19. No deaths were reported. Among 1283 siblings without MS, 79 (6.2%) had a reported diagnosis of COVID-19. … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|